BioCentury
ARTICLE | Politics & Policy

Pricing negotiations under AMNOG completed for 12 drugs

December 6, 2012 2:14 AM UTC

Germany's Statutory Health Insurance Funds Association (GKV-Spitzenverband) said pricing negotiations under drug pricing law AMNOG have been completed for 12 drugs. For 11 drugs, GKV-Spitzenverband and drug sponsors reached an agreement on a price; the price for ophthalmic drug Yellox bromenfac from Bausch + Lomb Inc. (Rochester, N.Y.) was determined through independent arbitration. GKV-Spitzenverband did not disclose the negotiated prices.

Drugs for which pricing negotiations have been completed include: Brilique ticagrelor from AstraZeneca plc (LSE:AZN; NYSE:AZN); Eliquis apixaban from Bristol-Myers Squibb Co. (NYSE:BMY) and Pfizer Inc. (NYSE:PFE); Esbriet pirfenidone from InterMune Inc. (NASDAQ:ITMN); Gilenya fingolimod from Novartis AG (NYSE:NVS; SIX:NOVN); Halaven eribulin from Eisai Co. Ltd. (Tokyo:4523; Osaka:4523); Incivo telaprevir from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) and Johnson & Johnson (NYSE:JNJ); Jevtana cabazitaxel from Sanofi (Euronext:SAN; NYSE:SNY); Rapiscan regadenoson from Rapidscan Pharma Solutions Inc. (Los Altos, Calif.); Victrelis boceprevir from Merck & Co Inc. (NYSE:MRK); Vyndaqel tafamidis from Pfizer; and Zytiga abiraterone from J&J. ...